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Cell death is a natural process for the turnover of aged cells, but it can also arise as a result of pathological conditions. Cell 
death is recognized as a key feature in both acute and chronic hepatobiliary diseases caused by drug, alcohol, and fat uptake; by 
viral infection; or after surgical intervention. In the case of chronic disease, cell death can lead to (chronic) secondary inflam-
mation, cirrhosis, and the progression to liver cancer. In liver transplantation, graft preservation and ischemia/reperfusion 
injury are associated with acute cell death. In both cases, so-called programmed cell death modalities are involved. Several 
distinct types of programmed cell death have been described of which apoptosis and necroptosis are the most well known. 
Parenchymal liver cells, including hepatocytes and cholangiocytes, are susceptible to both apoptosis and necroptosis, which are 
triggered by distinct signal transduction pathways. Apoptosis is dependent on a proteolytic cascade of caspase enzymes, whereas 
necroptosis induction is caspase-independent. Moreover, different from the “silent” apoptotic cell death, necroptosis can 
cause a secondary inflammatory cascade, so-called necroinflammation, triggered by the release of various damage-associated 
molecular patterns (DAMPs). These DAMPs activate the innate immune system, leading to both local and systemic inflam-
matory responses, which can even cause remote organ failure. Therapeutic targeting of necroptosis by pharmacological inhibi-
tors, such as necrostatin-1, shows variable effects in different disease models.
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In this review, we will discuss the mechanisms of 
necroptosis, and we will focus on liver transplantation 
and liver diseases, such as acute liver failure, fatty liver 
diseases, cholestatic liver diseases, chronic viral hep-
atitis, and primary liver cancer. Furthermore, we will 
review the clinical relevance of necroptotic cell death 
and its therapeutic potential by targeting cell death in 
liver diseases.
Cell death is a fundamental process that is essential 
in embryonic and (neo)natal development and homeo-
stasis in all organs, including the liver. Cell death is a 
means of removing aged and damaged cells that other-
wise might play a role in organ dysfunction and cancer 
development. For instance, if transformed hepatocytes 
with genetic aberrations become resistant to cell death, 
this may lead to cancer initiation and tumorigene-
sis.(1) In response to the overwhelming cellular stress, 
hepatocytes can die through active suicide, termed 
“apoptosis.” Another type of cell death, termed “necro-
sis,” is a more passive killing of cells. Apoptosis is char-
acterized by a cascade of specific intracellular events 
leading to so-called programmed cell death, whereas 
necrosis occurs as a consequence of extracellular events 
leading to physical damage and nonregulated (nonpro-
grammed) cell death.(2) In addition to apoptosis and 
necrosis, a new form of cell death that shared both 
proporties of apoptosis and necrosis was identified 
approximately a decade ago. This form of programmed 
necrosis has been termed “necroptosis.” The molecular 
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events involved in necrosis, programmed apoptotic, 
and necroptotic cell death are summarized in Fig. 1.
Necroptosis is characterized as an active and 
well-regulated form of necrosis that is morpholog-
ically and biochemically distinct from apoptosis. A 
special feature of necroptosis is the loss of integrity 
of the plasma membrane and subsequent release of 
damage-associated molecular patterns (DAMPs), 
triggering inflammation and exacerbating tissue dam-
age, ie, so-called necroinflammation.(3) Necroptosis is 
one of the main contributors to necroinflammation. 
Inflammation and the subsequent immunological 
response play an important role in many liver diseases 
as well as in ischemia/reperfusion injury (IRI) or rejec-
tion after liver transplantation. Necroptosis is increas-
ingly considered to play a role in the pathophysiology 
of these processes, and insight into necroptosis offers 
promising therapeutic intervention methods to treat 
liver diseases by targeting necroptosis. For instance, 
in hepatocellular carcinoma (HCC) or biliary cancer, 
resistance to apoptosis severely hampers the efficacy 
of chemotherapy (due to anticancer drug resistance). 
In this field, the pharmacological switch of cell death 
toward necroptosis may lead to therapeutic applica-
tions in drug-resistant cancers. This review focuses on 
necroptosis and summarizes not only related regulatory 
mechanisms but also the clinical relevance and bench-
to-bedside translational potential in liver diseases and 
liver transplantation.
Mechanisms of Necroptosis
Necroptosis can be initiated by a range of factors, 
such as IRI, release of reactive oxygen species 
(ROS), antineoplastic events, and calcium over-
load.(4) Furthermore, intracellular factors, such as 
tumor necrosis factor α (TNF-α), Fas ligand, tumor 
necrosis factor–related apoptosis-inducing ligand 
(TRAIL), interferon γ (IFNγ), double-stranded 
RNA, and adenosine triphosphate (ATP) depletion, 
are also known to be involved in inducing necro-
ptosis.(5) The binding of TNF-α to tumor necrosis 
factor receptor 1 (TNFR1) is one of the most ex-
tensively studied signaling pathways promoting not 
only necroptosis but also apoptosis and activation 
of the nuclear factor kappa B (NF-κB) pathway 
(Fig. 1A, left side).(6) Generally, TNF-α can trigger 
the formation of prosurvival- and proinflammatory- 
related complexes and caspase-dependent apoptosis.(7) 
Specifically, TNFR1 recruits TNFR1-associated death 
domain (TRADD) protein, tumor necrosis factor 
receptor–associated factor 2 (TRAF2), receptor- 
interacting serine/threonine-protein kinase (RIPK) 
1, cellular inhibitor of apoptosis protein (cIAP) 1/2, 
and the linear ubiquitin chain assembly complex 
(LUBAC) to form the complex I, which contributes 
to the activation of the NF-κB signaling pathway.(8) 
After dissociation from TNFR1, complex I will be 
transformed into complex IIa (comprising TRADD, 
Fas-associated protein with death domain [FADD], 
FLICE-inhibitory protein [FLIP], and procaspase 
8), leading to activation of caspase 8 and render-
ing RIPK1-independent apoptosis.(9) Conversely, 
the formation of complex IIb, consisting of RIPK1, 
RIPK3, FADD, FLIPs, and caspase 8, can be pro-
moted by knockdown of the nuclear factor kappa B 
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essential modulator (NEMO), blockage of cIAPs, 
or transforming growth factor β–activated kinase 
1 (TAK1).(10) Hyperactivation of cylindromatosis 
deubiquitinates RIPK1 and, thus, destabilizes com-
plex I, promoting the formation of complex IIb, 
which is involved in RIPK1-dependent apoptosis.(11) 
However, when caspase 8 is down-regulated or in-
hibited, RIPK3 is activated to interact with RIPK1, 
which binds to mixed lineage kinase domain-like 
(MLKL). Together, this forms the cytosolic com-
plex IIc (necrosome) by which necroptosis is initi-
ated (Fig. 1A, right side).(12) Necrostatin (Nec)–1 
is a well-investigated inhibitor of necroptosis by 
targeting the catalytic and allosteric functions of 
RIPK1,(13) and with that, preventing the formation 
of the necrosome.
From the above, it is clear that RIPK1 and RIPK3 
do not play an exclusive role in the modulation of cell 
death. Moreover, RIPK1 is the switch node between 
the prosurvival pathway and apoptosis and/or necrop-
tosis.(14) As the ultimate execution step, RIPK3 phos-
phorylates MLKL in the complex IIc and thereby 
triggers oligomerization of MLKL, which is indis-
pensable for its translocation to the plasma mem-
brane.(15) These oligomers can destabilize the plasma 
membrane through a pore-forming complex or by 
incapacitating Ca2+ or Na+ channels indirectly.(16) The 
late permeabilization step, characterized by an increase 
FiG. 1. Distinct molecular and morphologic features of apoptotic, necroptotic, and necrotic cell death. (A) Molecular pathways of 
cell death in PLCs. The binding of TNF-α and TNFR1 recruits TRADD, TRAF2, RIPK1, cIAP1/2, and LUBAC and forms the 
complex I leading to the activation of the NF-κB signaling and a prosurvival pathway. Following the dissociation from TNFR1, 
complex I is transformed into complex IIa, which includes TRADD, FADD, FLIPs, and procaspase 8, and contributes to the activation 
of caspase 8 and subsequent RIPK1-independent apoptosis. Hyperactivation of cylindromatosis (CYLD) deubiquitinates RIPK1 and 
thus destabilizes complex I and promotes the formation of complex IIb, which is involved in RIPK1-dependent apoptosis. Complex 
IIb consists of RIPK1, RIPK3, FADD, FLIPs, and caspase 8, and it can be promoted by inhibition of NEMO, cIAPs, or TAK1. 
Nevertheless, once caspase 8 is inhibited, RIPK3 is activated to interact with RIPK1 and binds to MLKL, forming the complex IIc 
(necrosome) by which necroptosis is promoted. RIPK3 phosphorylates MLKL in the complex IIc and thereby triggers oligomerization 
of MLKL, driving the permeabilization step. Nonprogrammed cell death by necrosis is characterized by mitochondrial impairment 
with resulting ATP depletion and triggering of the ROS-JNK loop. After the cell membrane ruptures in necrotic or necroptotic cells, 
intracellular DAMPs are released and act as activators and amplifiers of necroinflammation. Conversely, release of a lower amount 
of DAMPs from apoptotic cells leads to much milder necroinflammation. (B) Summary of hallmark events and characteristics of cell 
survival and cell death by apoptosis, necroptosis, or necrosis.
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of intracellular osmotic pressure and the opening of 
membrane pores, represents one of the hallmarks of 
necroptotic cell death.(17)
Necroinflammation is a form of sterile inflam-
mation triggered by DAMPs that are released from 
necrotic cells through the ruptured membrane. 
Necroptosis is one of the most important initia-
tors. DAMPs act as activators and amplifiers of the 
inflammation response(18) and can be categorized 
into 2 groups:
1. Molecules with no inflammatory activity in normal 
cells but which, upon release, exhibit immune 
activity (ie, heat shock proteins and extracellular 
ATP).
2. Alarmins that exhibit specific cytokines initiating 
an inflammatory response once released (ie, inter-
leukin [IL] 1α and IL33).
DAMPs are recognized by a series of receptors 
called “pattern recognition receptors,” such as toll-like 
receptors (TLRs) and nucleotide oligomerization do-
main-like receptors, which activate the innate immu-
nity and thereby evoke the release of cytokines that, 
in turn, induce more necrosis and trigger an inflam-
matory cascade reaction.(19) This vicious inflammatory 
circle is strongly associated with the development of 
chronic liver disease and liver fibrosis(3) and is involved 
in acute liver injury, graft injury, and rejection after 
liver transplantation.(20)
Necroptosis in Liver 
Diseases
DRUG-inDUceD liveR inJURY
Drug-induced liver injury is mostly caused by acet-
aminophen (APAP) toxicity.(21) It has been reported 
that necrosis, independent of caspase and the TNF 
receptor, is mostly involved in APAP-induced liver 
injury(22) and that the role of apoptosis is limited as 
was demonstrated by the insensitivity to caspase in-
hibitors (Table 1).(32) In a murine model, both ge-
netic blockage and chemical inhibition of RIPK1 
could ameliorate APAP-induced liver injury.(27) In 
contrast, Li et al.(31) reported that neither Nec-1 nor 
RIPK1 silencing was able to protect human hepato-
cytes from cell death, suggesting a differential role of 
RIPK1 in mice or humans undergoing APAP-induced 
liver injury. Likewise, Ramachandran et al.(25) 
demonstrated that RIPK3 is an early mediator of 
drug-induced liver injury. Knockout of RIPK3 pro-
tected mice from APAP toxicity but only during a 
very short time frame (no more than 24 hours in 
vivo and 48 hours in vitro). One potential explana-
tion for this is that the abrogation of RIPK3 can-
not alleviate the secondary injury that occurs after 
APAP overdose.(33) Deutsch et al.(28) also reported 
increased expression of RIPK3 in liver tissue of pa-
tients with hepatic failure caused by APAP over-
dose. Silencing or chemical inhibition of RIPK3 
protects human hepatocytes from drug-induced liver 
injury.(31) However, a study by Dara et al.(23) shows 
that knockout of RIPK3 did not alleviate liver in-
jury and the activation of RIPK3 is not observed 
in the murine APAP-induced liver injury model. 
Furthermore, they also reported that the MLKL 
messenger RNA (mRNA) level is elevated quickly 
after APAP treatment and knockout of MLKL can-
not rescue mice from APAP-induced liver injury,(23) 
demonstrating that the up-regulation of MLKL is 
not the mediator but the consequence of APAP tox-
icity. Therefore, the involvement of necroptosis in 
APAP-induced liver injury is still questionable. The 
role of RIPK1 independent of RIPK3 and MLKL in 
such injury needs to be clarified. Moreover, further 
investigation should focus not only on animal mod-
els but should also include clinical human samples 




Immune-mediated liver injury plays a critical role in 
liver diseases through innate and adaptive immune 
responses. Specifically, autoimmune hepatitis (AIH) 
is a severe necroinflammatory liver disease that pro-
gressively contributes to liver failure and mortality.(34) 
Administration of the lectin concanavalin A (ConA), 
a T cell mitogen, to mice is the most used model to 
study immune-mediated liver injury. Typically, in this 
model, early stage apoptosis is followed by massive ne-
crosis at later stages. The kinase activity of RIPK1 is 
elevated when stimulated with ConA and cell death is 
caspase-independent.(35) However, knockout of RIPK1 
in parenchymal liver cells (PLCs) could not rescue liver 
damage because of exacerbated TNF-α–mediated and 
caspase-dependent apoptosis (Table 2).(28) Actually, 
under steady-state conditions, RIPK1 also functions 
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as a scaffold protecting hepatocytes from apoptosis 
through NF-κB activation or NF-κB-independent 
pathways.(40) This means that RIPK1 plays a dual role 
in the ConA-induced liver injury. Deutsch et al.(28) 
reported the elevated expression of RIPK3 in liver 
tissue of AIH patients, but genetic silence of RIPK3 
in a murine model could not relieve ConA hepatitis. 
Conversely, Kang et al.(38) demonstrated that genetic 
silencing of RIPK3 reduced the ConA-induced eleva-
tion of serum aminotransferase concentrations as well 
as inflammatory markers such as IFNγ and TNF pro-
tein. This discrepancy may arise from using different 
gene modification strategies in these studies. Actually, 
as reported by Kang et al.,(38) the expression of RIPK3 
tABle 1. necroptosis in ApAp-induced liver injury
Researchers Subject (Mice) APAP Treatment Findings
Dara et al.(23) Male C57BL/6n 300 mg/kg IP • RIPK1 knockout protects mice from APAP toxicity, but no protection is found in  
knockout of RIPK3 or MLKL mice.
• RIPK1, but not RIPK3, level in cytoplasm increases after APAP treatment in PMH.
• High expression of RIPK3 in NPC but low expression in PMH.
• Protection of Nec-1 in vitro and in vivo.
• JNK acts downstream of RIPK-dependent necrotic signaling.
An et al.(24) Male C57BL/6 300 mg/kg IP • APAP triggers hepatic caspase-independent and RIPK-dependent necrosis.
• RIPK1 and RIPK3 increase after APAP treatment, but RIPK3 increases earlier than 
RIPK1.
• JNK acts downstream of RIPK-dependent necrotic signaling.
• Both Nec-1 and JNK inhibitor protect mice from lethal APAP intoxication.
• Nec-1 can decrease RIPK1 and RIPK3 expression after APAP treatment, but JNK  
inhibitor cannot.
• RIPK3 is absent in liver lysates from untreated mice.
Ramachandran  
et al.(25)
Male C57Bl/6J 200 mg/kg IP • RIPK3 increases early after APAP treatment.
• RIPK3 inhibition reduces cellular necrosis, accompanied with reduced mitochondrial 
oxidant stress, JNK activation, and Drp1 translocation.
• Protective effect of RIPK3 knockout is lost at 24 hours in vivo and 48 hours in vitro.
• Protective effect of Nec-1 is lost at 48 hours in vitro.
• Protection of RIPK3 knockout is not caused by inhibition of protein adduct formation.
Takemoto et al.(26) Male C57BL/6 800 mg/kg IP • RIPK1 and RIPK3 increase after APAP treatment and are colocalized with CYP2E1.
• Nec-1 protects against APAP-induced hepatic injury in vivo and in vitro by inhibiting 
ROS production and suppresses mitochondrial dysfunction.
Zhang et al.(27) Male C57Bl/6J 300 mg/kg IP • Dabrafenib protects mice and human hepatocytes from APAP hepatotoxicity by  
inhibiting RIPK3.
• RIPK3 silencing partially reversed the APAP-induced loss of the cell viability of  
QSG-7701 cells and HL-7702, 2 kinds of human hepatocyte cell lines.
• Nec-1 inhibition or RIPK1 silencing did not reduce APAP-induced cell death in human 
hepatocyte cells.
Deutsch et al.(28) Male C57BL/6 500 mg/kg IP • Blockade of RIPK1 or RIPK3 ameliorates APAP toxicity.
• RIPK1 and RIPK3 are absent in normal hepatocytes but extensively expressed in the 
liver from APAP-treated mice.
• Elevated expression of RIP3 occurs in the liver of patients with hepatic failure from 
severe APAP toxicity, but expression was absent in the normal human liver.
• Nec-1s was similarly protective against APAP injury.
• NLRP3−/− mice are protected from APAP injury.
• Blockade of RIPK1 and RIPK3 diminishes inflammasome activation, immune cell 
infiltration, and sterile inflammation after APAP administration.
Yan et al.(29) Male C57BL/6 300 mg/kg IP • RIPK3 and MLKL mRNA increase at 2 hours after APAP treatment.
• Knockout of RIPK3 cannot alleviate APAP toxicity.
• A pan caspase inhibitor (Z-VAD-FMK), but not Nec-1, inhibits TNFα/APAP-induced 
cytotoxicity on human fetal hepatocyte line (LO2) cells a kind of normal hepatic cell 
line.
Lee et al.(30) C3H/He 400 mg/kg po • No change of RIPK1 level is found after APAP treatment compared with control mice.
• RIPK3 is not expressed in the livers of normal control mice but increases after APAP 
treatment.
Li et al.(31) Male C57Bl/6J 300 mg/kg IP • Dabrafenib targets RIPK3 and disrupts the interaction between RIPK3 and MLKL and 
exhibits an inhibitor of necroptosis.
• Dabrafenib prevents APAP-induced necrosis in normal human hepatocytes.
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in natural killer T cells (NKTs) is much higher com-
pared with hepatocytes. RIPK3 is involved in the 
function of NKTs, a crucial step in ConA hepatitis, 
through activation of RIPK3–phosphoglycerate mu-
tase 5 (PGAM5)–dynamin-related protein 1 (Drp1)/
nuclear factor of activated T cell signaling. This is in 
accordance with results of He et al.(41) that showed that 
PGAM5-Drp1 axis–mediated mitochondrial fission 
drives the hepatic necrosis in ConA hepatitis. In addi-
tion, pseudokinase mixed-lineage kinase domain-like 
(pMLKL) has been reported to be elevated in human 
AIH biopsies, and in murine models, it has been proven 
that ConA hepatitis is driven by an MLKL-dependent 
pathway that occurs independent of RIPK3.(42) Taken 
together, the actual pathway of programmed necrosis 
during ConA hepatitis is still not clear. Although the 




Liedtke et al.(36) Unclear 25 mg/kg IV • Caspase 8 deletion protects against Fas- and LPS-mediated liver injury but enhances 
nonapoptotic liver injury.
• High RIPK1 is expressed upon ConA treatment.
• FADD-RIPK1-RIPK3 complex is promoted upon ConA treatment in caspase 8–deleted mice.
• Caspase 8 deletion was protective when ConA was administered together with GalN, 
which induces apoptosis in addition to necrosis.
• JNK signaling is also associated with necrosis induction in these animals.
• Deletion of both caspase 8 and NEMO protects against steatosis and hepatocarcinogenesis 
but triggers massive liver necrosis, cholestasis, and biliary lesions.
Jouan-Lanhouet 
et al.(37)
Female C57Bl/6 20 mg/kg ROA • PARP-1 is activated in ConA-induced hepatitis.
• ConA-induced hepatitis is inhibited by Nec-1 or PJ-34 (a pharmacological inhibitor of 
PARP-1) pretreatment.
Kang et al.(38) C57Bl/6 20 mg/kg IP • Both deletion of RIPK3 and pharmacological inhibition of Drp1 protect mice from NKT-
mediated induction of acute liver damage.
• PGAM5 is a key mediator of RIPK3-mediated activation of NKT cells but does not play a 
role in necroptosis.
• RIPK3 deficiency reduces transaminase levels, inflammatory cell infiltrates, and apoptotic 
cells in ConA-treated mice.
• Mice lacking TNFR1 are resistant to ConA-induced liver injury and inflammation.
• RIPK1 does not play a role in RIPK3-dependent activation of cytokine production.
Deutsch et al.(28) Male C57BL/6 20 mg/kg IV • RIPK1 and RIPK3 expression is elevated in mice with ConA hepatitis.
• RIPK3 deletion can only protect against early injury of ConA hepatitis.
• RIPK1 deletion markedly exacerbates ConA hepatitis, resulting in increased apoptotic cell 
death in the liver but can also reduce intrahepatic inflammatory infiltrate.
• Expression of RIPK3 is elevated in the liver of patients with hepatic failure from AIH.
• Exacerbation of hepatocyte injury is found in ConA plus Nec-1–treated mice and can be 
protected by caspase 8 blockage.
Filliol et al.(35) Male C57BL/6 20 mg/kg IV • ConA treatment in mice can induce TRAIL-mediated caspase-independent cell death of 
hepatocytes and be partially prevented by co-treatment of Nec-1.
• RIPK1 kinase activity drives hepatocyte necroptosis following ConA injection but also 
serves as a scaffold protecting hepatocytes from massive apoptosis in the same model.
• Blockage of RIPK1 in mice triggers TNF-α–promoted apoptosis and can be protected by 
caspase inhibitor.
Le Cann et al.(39) C57Bl/6 12 mg/kg IV • Both Sibiriline and Nec-1s can significantly decrease liver damage by reducing the size of 
perivascular and parenchymal zones of necrosis in ConA hepatitis.
Filliol et al.(40) Alfp-Cre transgenic 
mice
12 mg/kg IP • RIPK1 deletion sensitizes mice to Fas-induced liver injury due to increased hepatocyte 
apoptosis.
• Hepatolysis is observed in RIPK1-deleted mice upon being treated with ConA.
He et al.(41) Unclear 25 mg/kg IV • Hepatic PGAM5 mRNA levels were elevated in patients suffering from AIH.
• ConA-induced liver inflammation was associated with elevated levels of PGAM5 protein in 
liver tissues.
• PGAM5 deletion protects mice from ConA-induced hepatocellular necrosis and liver injury 
downstream of inflammatory cell infiltration and activation.
• T cells activated by ConA produce high levels of cytokines, including IFNγ, TNF-α, and IL2.
• PGAM5 deficiency protects mice from ConA-induced liver injury downstream of inflamma-
tory cell infiltration and activation.
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involvement of necroptotic mediators, such as RIPK1, 
RIPK3, and MLKL, has been reported, they are more 
likely to exhibit independent roles in diverse signaling 
pathways that drive programmed necrosis. Moreover, 
as demonstrated by Liedtke et al.,(36) simultaneous 
blockage of RIPK1 and caspase 8 during ConA hep-
atitis completely inhibited liver injury by suppressing 
necrosis as well as apoptosis and might be a potential 
therapy for immune-mediated liver injury.
FAttY liveR DiSeASeS
Nonalcoholic fatty liver disease (NAFLD) is a com-
mon pathological condition associated with obesity, 
diabetes, and metabolic syndrome, resulting in fat ac-
cumulation in the liver without the history of alcohol 
abuse. NAFLD can develop into nonalcoholic steato-
hepatitis (NASH), where fat accumulation triggers 
inflammation (hepatitis).(43) NAFLD/NASH is cur-
rently the most rapidly expanding indication for liver 
transplantation in developed countries. Progressive 
steatohepatitis is associated with extensive apoptosis 
in hepatocytes induced by free fatty acids.(44) Several 
novel agents inhibiting apoptosis have been applied 
in clinical trials, but no significant protective effect 
was observed so far.(45,46) In addition, inhibition of 
apoptosis by blocking caspase 8 in a murine model for 
alcohol-induced liver injury could not mitigate hepatic 
cell death, which might imply a possible switch from 
apoptosis to necroptosis.(47) This is in line with results 
of Gautheron et al.(48) that showed that deletion of 
caspase 8 renders mice more susceptible to methionine- 
choline-deficient (MCD) diet–induced liver steatosis, 
including extensively increased RIPK3 expression and 
subsequent massive liver injury and fibrosis. In concor-
dance with these mouse models, significant elevation 
of RIPK3 in liver biopsies from NASH and NAFLD 
patients has also been reported.(48,49) Circulating 
RIPK3, pMLKL, and necrosis markers were also 
found to be increased in the serum of NAFLD pa-
tients.(49) Deficiency of RIPK3 attenuates murine 
MCD-induced liver injury, steatosis, inflammation, 
fibrosis, and oxidative stress.(49) However, in mice that 
were fed a high-fat diet (HFD) to induce NAFLD, 
the absence of RIPK3 exacerbated liver injury with 
increased inflammation and hepatocyte apoptosis as 
well as early fibrotic responses.(50) The discrepancy 
between these findings may arise from the difference 
between the MCD and HFD models. Generally, mice 
treated with HFD exhibit glucose intolerance and 
insulin resistance similar to NAFLD patients, whereas 
MCD-fed mice do not show these features and might 
be a more appropriate model for NASH.(51) This also 
reveals the potential different role of necroptosis in 
NASH and NAFLD patients. In further studies on 
NASH/NAFLD as well as other disease models, the 
differences between the various types of cell death 
and also a careful evaluation of using the right model 
should obviously be taken into consideration.
choleStAtic DiSeASeS
Cholestatic diseases are defined by a reduction in 
bile f low caused by impaired secretion by hepato-
cytes or cessation in bile f low through intrahepatic 
or extrahepatic bile ducts. Cholestasis often occurs 
as a result of chronic liver and biliary diseases, such 
as hepatitis, primary sclerosing cholangitis, primary 
biliary cirrhosis, and graft-versus-host disease.(52) 
Accumulation of toxic bile acids can induce apop-
tosis of both hepatocytes and cholangiocytes and is 
strongly associated with hepatocarcinogenesis as was 
shown in a rodent model.(53) Unfortunately, potent 
caspase inhibitors could only moderately alleviate 
liver injury after bile duct ligation, which implies 
that apoptosis is not the only type of cell death in 
cholestasis. As also described for NAFLD/NASH, 
a switch to necroptosis may occur in cholestatic dis-
eases.(54) Afonso et al.(55) reported high expression 
levels of RIPK3 and MLKL in primary biliary cirrho-
sis patients, demonstrating the occurrence of necro-
ptosis in this disease. They also found that RIPK3 
deficiency could inhibit necroinf lammation that oc-
curred during bile duct ligation. Actually, in the case 
of cholestasis, caspase 8–dependent apoptosis was 
found to drive compensatory proliferation in hepato-
cytes and nonparenchymal cells (NPCs) through 
c-Jun N-terminal kinase (JNK) activation. However, 
when the necroptotic pathway is triggered, activation 
of RIPK3 inhibits caspase 8–dependent activation of 
JNK in both PLCs and non-PLCs. This, in turn, 
limits the immune response and compensatory pro-
liferation of PLCs. Subsequently, the development 
of jaundice and cholestasis is promoted, and inf lam-
matory hepatocarcinogenesis is impeded.(56) Another 
study also showed that inactivated phosphorylation 
of RIPK1 in PLCs inhibits the compensatory prolif-
eration of both hepatocytes and intrahepatic biliary 
cells, which promotes cholestasis.(57) This indicates 
the possible independent role of RIPK1 and RIPK3 
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in cholestatic diseases, which needs to be clarified in 
further studies.
viRAl hepAtitiS
Chronic viral hepatitis (hepatitis B virus [HBV] and 
hepatitis C virus [HCV]) is a major cause of chronic 
liver disease worldwide. HBV/HCV–related liver in-
jury constitutes a major risk factor for cirrhosis and 
HCC.(58) Necroinflammation in viral hepatitis is 
strongly associated with liver fibrosis progression and 
hepatocarcinogenesis.(58,59) However, the mechanism 
of both necroptosis and necroinflammation in chronic 
viral hepatitis remains unclear due to a limited num-
ber of studies. Afonso et al.(49) demonstrated high 
expression of RIPK3 in liver tissue from HBV and 
HCV patients by immunostaining, which indicates 
the potential involvement of necroptosis in chronic 
viral hepatitis. HCV has been proven to influence the 
death receptor–mediated pathway and the apoptotic 
pathway. Consequently, caspase inhibitors, such as 
IDN-6556 (Emricasan, a caspase inhibitor), were re-
ported to be used as a potential therapy,(60) but again, 
the possible necroptotic switch should also be taken 
into account here. Lim et al.(61) found that the HCV-
induced cell death of human hepatoma cells could be 
rescued not only using a pancaspase inhibitor but also 
by Nec-1. However, the researchers did not provide ev-
idence for the type of cell death involved. In addition, 
HBV-related hepatoma cell lines have been described 
to express high levels of apoptosis inhibitors, which 
may explain the resistance of HCC-HBV to apopto-
sis induction therapy.(62) The HBV X protein–induced 
microRNA (miRNA) 21 could suppresses cell apop-
tosis in HCC by targeting IL12.(63) In addition, HBV 
core protein could also inhibit Fas-mediated apopto-
sis in HCC by regulating membrane-bound Fas/Fas 
ligand and soluble Fas expression.(64) Taken together, 
this implies that targeting necroptosis might be fur-
ther explored as a potentially interesting therapy for 
HBV-related HCC-HBV.
liveR cAnceR
HCC and cholangiocarcinoma (CCA) are the most 
common primary malignancies in the liver. They 
differ markedly in their morphology, metastatic 
 potential, and responses to therapy. It has been sug-
gested that both forms may arise from liver progen-
itor cells and have potentially overlapping pathways 
of oncogenesis.(1) The regulatory molecules and tissue 
context that commit transformed hepatic cells toward 
HCC or CCA are still largely unknown, but a recent 
mouse study showed that hepatocytes with aberrantly 
activated oncogenes give rise to CCA when embed-
ded in a necroptosis-dominated hepatic microenviron-
ment.(65) DAMPs released by necroptotic hepatocytes 
can activate immune cells to secrete various specific 
cytokines to form a robust inflammatory environment, 
determining the outgrowth of CCA from transformed 
hepatocytes. In contrast, hepatocytes that harbor the 
same oncogenic driver will give rise to HCC if it is 
not adjacent to necroptotic hepatocytes. Notably, dif-
ferent from hepatocytes, transformed cholangiocytes 
can only develop into CCA and not HCC.(66) This 
finding may explain why CCA exhibits resistance to 
apoptosis, which is possibly due to higher endogenic 
expression of myeloid cell leukemia 1.(61) Further work 
is warranted to unravel the extracellular and intracel-
lular mechanisms and interactions between cytokines 
and transformed hepatocytes in detail, which, in turn, 
will be helpful to find new targeted therapies against 
HCC and CCA.
Necroptosis in Liver 
Transplantation
Liver transplantation is widely accepted as the only 
effective intervention for patients with end-stage 
liver disease. During liver transplantation, IRI is 
inevitable, although ischemia-free transplantations 
are feasible as described recently.(67) IRI is a detri-
mental process that not only damages the liver graft 
but is also associated with distant organ damage, 
such as acute kidney injury after liver transplanta-
tion.(68) Apoptosis and necrosis are the 2 most im-
portant types of cell death related to IRI. With strict 
morphological criteria, Gujral et al.(69) demonstrated 
that only a small subset of sinusoidal endothelial 
cells and hepatocytes underwent apoptosis after 
warm ischemia followed by reperfusion. Necrosis 
appears to be the dominant type of cell death in IRI, 
especially during reperfusion injury, accounting for 
more than 90% of total cell death and, consequently, 
caspase inhibitors cannot prevent IRI-related cell 
death. A schematic overview of necroptosis in liver 
transplantation is shown in Fig. 2. Haga et al.(70) 
demonstrated that hypoxia/reoxygenation leads to 
an increased expression of necroptosis mediators in 
murine liver cell lines, which subsequently could be 
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inhibited by Nec-1. Several studies also interpret 
the role of necroptosis in IRI using a mouse hepatic 
IRI model. Hong et al.(71) reported that RIPK1 and 
RIPK3 expression is dramatically increased and is 
accompanied by the formation of the RIPK1/RIPK3 
complex after IRI. Treatment with Nec-1 not only 
mitigated necroptosis but also decreased the serum 
levels of TNF-α and IL6. Nevertheless, 2 other 
studies done using similar animal models reveal the 
converse conclusion that necroptosis is not involved 
in the IRI process,(72,73) demonstrating controver-
sial findings resulting in unclear and contradicting 
conclusions in this field. Also, there is no protective 
effect observed after administration of Nec-1 or cy-
closporine A, which is an inhibitor of mitochondrial 
permeability transition. This indicates that neither 
necroptosis nor mitochondrial permeability tran-
sition contributes to necrosis in hepatic IRI. This 
contradictory conclusion may arise from variations 
during the establishment of the model and needs 
more careful analysis. Administration of Nec-1 be-
fore ischemia occurs or before reperfusion is done 
might also explain this discrepancy in results be-
cause the injury type and signaling are differential 
in various stages during transplantation surgery.(69) 
Furthermore, Liss et al.(74) found that hepatic IRI in 
the setting of steatosis led to increased expression of 
RIPK1, RIPK3, and MLKL, which might indicate 
the potential involvement of necroptosis in IRI in 
steatotic liver grafts.
Necroinflammation resulting from IRI has proven 
to determine the fate of the liver graft and the out-
come of patients undergoing liver transplantation 
(Fig. 2). Necroptosis is one of the critical triggers of 
necroinflammation, though its role in hepatic IRI 
is still unclear. Following hepatic IRI, DAMPs are 
released from necrotic cells and exacerbate inflamma-
tion and liver injury.(75) Activation of TLRs by DAMPs 
FiG. 2. Schematic overview of necrosis and necroinflammation during liver transplantation. During ischemia and reperfusion injury, 
both necroptosis and necrosis of PLCs can occur. Rupture of the cell membrane facilitates the release of intracellular DAMPs and 
subsequent inf lammatory responses. TLRs on both KCs and DCs are activated that promote the production and release of cytokines 
and chemokines. This will trigger migration of innate immune cells to the liver graft but also give rise to necrotic spread by further 
induction of necroptosis in surrounding cells. This necrotic spread could cause early allograft dysfunction or total graft failure causing 
primary nonfunction. Furthermore, this necrotic spread and necroinflammation can lead to remote organ injury outside the graft. 
Robust innate immunity can also active host T cells and evoke adaptive immune response that is associated with acute and chronic 
rejection after transplantation.
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also recruits innate immune cells to the graft and ulti-
mately contributes to graft rejection.(76) High-mobility 
group box 1 (HMGB1), a nuclear protein regulating 
transcription, is one of the most-investigated DAMPs, 
which binds to TLR4 and induces the generation 
of proinflammatory cytokines and subsequent graft 
liver damage.(77) Increased plasma levels of HMGB1 
are a marker of hepatocellular injury in recipients.(78) 
Down-regulation of nuclear HMGB1 by small inter-
fering RNA in a mouse IRI model protected the liver 
from IRI and alleviated inflammation response.(79) 
Moreover, a clinical trial demonstrated that a TLR4 
single-nucleotide polymorphism, leading to dimin-
ished binding with HMGB1, reduced the risk of graft 
loss after liver transplantation.(80) In general, necroin-
flammation is a promising new therapeutic target for 
liver transplantation. Furthermore, the booming devel-
opment of ex vivo normothermic machine perfusion 
should also be addressed because this can provide an 
appropriate model for the investigation on necroptosis 
and necroinflammation in human liver grafts.
Pharmacological Strategies 
Targeting Necroptosis
Although apoptosis inhibitors have been used in a clini-
cal trial against apoptosis-mediated liver injury, the pro-
tective effect of these inhibitors remains questionable 
and might be dependent on whether or not the switch 
from apoptosis to necroptosis is made.(81) Therefore, 
the clinical application of necroptosis inhibitors should 
also be considered. Nec-1 is the first and extensively 
used compound identified as an inhibitor of necroptosis 
acting on the kinase activity of RIPK1.(82) Because of 
its striking specificity for necroptosis, it is also widely 
interpreted as indicating proof of necroptosis in various 
conditions. However, even though Nec-1 was described 
more than a decade ago, it has only been used in preclin-
ical trials to treat amyotrophic lateral sclerosis.(83) Low 
potency and the short half-life of Nec-1 in vivo restrains 
its clinical application. Moreover, Nec-1 is not exclu-
sively inhibiting for necroptosis because it also acts on 
the indoleamine 2,3-dioxygenase (IDO) enzyme that 
regulates the innate and adaptive immune system.(84) 
Instead, the development of Nec-1s, which is more sta-
ble, has great potential in vivo. Nec-1s lacks IDO in-
hibitory activity and possesses a longer half-life in vivo 
than Nec-1, which makes Nec-1s more promising for 
bench-to-bed translation.(85) Administration of radio 
immunoprecipitation assay 56, another RIPK1 inhib-
itor, is also a potential therapy against necroptosis that 
has been validated in murine systemic inflammatory 
response syndrome.(86)
Considering the crosstalk of RIPK1 in apoptosis, 
necroptosis, and NF-κB pathways, inhibition of RIPK3 
kinase activity seems to be a more specific and therefore 
more potential therapeutic option targeting necroptosis. 
RIPK3 inhibitors can also be applied in some RIPK1-
independent pathologic conditions, such as viral infec-
tion and pancreatitis.(87) Compounds including low 
concentrations of GSKʹ840, GSKʹ843, GSKʹ872, and 
GW392 have been verified in vivo and in vitro to inhibit 
necroptosis.(82,88) However, RIPK3 inhibitors used in 
high concentrations might induce apoptosis by acti-
vating caspase 8.(89) Furthermore, necrosulfonamide, 
which targets MLKL, is found to inhibit necroptosis 
in vitro. More studies are needed to investigate the effi-
ciency and safety of necrosulfonamide in vivo.
Different from the above inhibitors, some drugs that 
are already used in the clinic also inhibit necroptosis 
activity. Their safety in patients has already been 
validated. For instance, dabrafenib is a US Food and 
Drug Administration–approved drug for metastatic 
melanoma treatment,(90) and Li et al.(31) demonstrated 
that dabrafenib could inhibit RIPK3 and alleviate 
APAP-induced liver injury in vitro and in vivo. Sorafenib 
is a clinically used drug to treat HCC and acute myeloid 
leukemia,(91) and it can inhibit both RIPK1 and RIPK3 
kinase activity and thus protects against TNF-induced 
systemic inflammatory response syndrome and kidney 
IRI.(92) Likewise, ponatinib and pazopanib, 2 anticancer 
agents, were also found to be inhibitors of necroptosis 
in human cells.(93) Phenytoin, a clinically used anti-
convulsant drug, can also block necroptosis in systemic 
inflammatory response syndrome and was shown to be 
efficient in a kidney IRI model. In addition, melatonin 
is synthesized endogenously by the pineal gland and 
functions as an indirect antioxidant. It has been demon-
strated to attenuate carbon tetrachloride–induced liver 
injury and to prevent fibrosis by inhibiting necroptosis- 
associated inflammatory signaling.(94)
Conclusion
In this review, we strived to illuminate the role of necro-
ptosis in acute and chronic liver diseases as well as in 
liver transplantation. Although our primary view was 
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on necroptosis, the crosstalk between apoptosis and 
necroptosis should not be ignored. In most cases, these 
2 types of cell death are intermixed in the pathogen-
esis of liver diseases, although the role of necroptosis 
in some liver diseases is still unconfirmed. The switch 
between apoptosis and necroptosis should be noted 
when using either caspase inhibitors or necroptosis 
inhibitors. For instance, caspase inhibitors can pre-
vent apoptosis but may induce necroptosis in turn, 
which gives rise to detrimental effects, ranging from 
less effectiveness to massive secondary inflammation 
response. Insight into necroptosis also offers a con-
vincing explanation for the limited clinical benefits 
of caspase inhibitors. Actually, necroptosis mediators, 
such as RIPK1 and RIPK3, can also be involved in 
other signaling pathways, mitochondrial dysfunction, 
and apoptosis. This highlights the difficulty to target 
cell death in pathological situations. Further studies 
should be focused on the investigation of the potential 
crosstalk between various cell-survival and cell-death 
signaling pathways in liver diseases. It is also notable 
that RIPK1, RIPK3, and MLKL could function inde-
pendently in some liver diseases, such as acute liver in-
jury and cholestatic diseases, through a nonnecroptosis 
pathway. What would be important to help the 
research field forward is consensus on the precise defi-
nition of necroptosis and its morphology and signal-
ing hallmarks. In addition, the results of some recent 
studies using experimental mouse models exhibit con-
troversial results, which could be caused by the dif-
ferences in genetic background of the mouse strains 
and the different experimental conditions used in the 
studies. For instance, in studies focusing on fatty liver 
disease, diverse treatment may very well lead to incon-
sistent results when choosing either MCD or HFD 
models. Related studies involving humans are still re-
stricted to clinical liver biopsies. It is also a promising 
direction to use in vitro experimental models derived 
from patients, such as organoids,(95,96) which represent 
individual or patient-specific pathological features. 
In addition, as a severe consequence of necroptosis, 
necroinflammation plays a crucial role in both acute 
and chronic liver diseases. Several of these DAMPs 
could serve as potential biomarkers for the evaluation 
of liver injury, for instance, during normothermic graft 
preservation by machine perfusion for liver transplan-
tation. In summary, necroptosis is a promising thera-
peutic target for treatment of liver diseases and during 
graft preservation and should be further explored both 
to deepen our understanding of how liver cells die and 
clarify the clinical perspective for translation of the 
knowledge in medical practice.
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